ABT News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AB

Mkt Cap

$177.55B

Volume

6.48M

Next Earnings

October 21st

Chart Financials Earnings News About Dividends Insider Filings

3 Dividend Stocks to Buy and Hold for 10 YearsThe article recommends three healthcare dividend stocks for long-term investors: Pfizer, Abbott Laboratories, and Medtronic. Despite recent challenges, all three companies offer strong dividend programs with growth potential. Pfizer has a promising pipeline including weight loss and cancer drugs. Abbott benefits from a diversified medical device business and recent acquisitions. Medtronic is positioned for growth through its cardiac ablation solutions and robotic surgery systems.The Motley Fool · Sep 18, 2026

Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees UpsideKen Griffin's Citadel hedge fund increased its AbbVie stake by over 500% in Q2 2026, signaling confidence in the pharmaceutical company's defensive qualities and dividend strength. AbbVie, a Dividend King with 50+ consecutive annual dividend increases, offers a 2.6% yield and has successfully navigated patent cliffs with new drugs like Skyrizi and Rinvoq. Wall Street analysts remain bullish with 25 of 31 rating it a buy and an average price target of $277.The Motley Fool · Sep 15, 2026

In Vitro Diagnostics MarketThe in vitro diagnostics market is undergoing structural transformation, shifting from centralized laboratory testing to decentralized point-of-care platforms. Valued at $96.5 billion in 2026 and forecast to reach $140.4 billion by 2033 at 5.5% CAGR, the market is increasingly driven by molecular diagnostics, software-driven interpretation, and recurring reagent revenue rather than instrument sales. Early movers securing decentralized placement and broad assay menus are establishing competitive advantages, while health systems must treat platform selection as strategic commitments rather than procurement events.GlobeNewswire Inc. · Sep 10, 2026

NVST or ABT: Which Is the Better Value Stock Right Now?In a comparison of two Medical Products stocks, Envista (NVST) emerges as the superior value option over Abbott (ABT). NVST holds a Zacks Rank #2 (Buy) with a Value grade of B, featuring a lower forward P/E ratio of 17.51 and PEG ratio of 1.28. ABT has a Zacks Rank #3 (Hold) with a Value grade of C, with higher valuations at P/E of 19.11 and PEG of 1.96. Based on stronger earnings outlook and more attractive valuation metrics, NVST is positioned as the better value investment.Zacks Investment Research · Sep 9, 2026

Medtronic Raises 2027 Outlook as Broad-Based Growth Gains MomentumMedtronic (MDT) raised its fiscal 2027 revenue growth guidance to 7.25%-7.75% following a strong first quarter with adjusted EPS of $1.45 (up 15.1% YoY) and revenues of $9.76 billion (up 13.7%). The company's recent acquisitions in neurovascular and pain markets add exposure to faster-growing segments. However, margin expansion remains challenged by unfavorable product mix and tariff pressures, with management targeting only 50 basis points of improvement.Zacks Investment Research · Sep 9, 2026

1 No-Brainer ETF I'm Loading Up on in 2026 and BeyondThe Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive passive income potential. The ETF has delivered 29% total returns year-to-date and is particularly suitable for tax-advantaged accounts like Roth IRAs.The Motley Fool · Sep 8, 2026

If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend KingAbbott Laboratories, a Dividend King with 54 consecutive years of dividend increases, is positioned as a defensive investment for potential market downturns. The company reported strong Q2 results with 13% sales growth and raised its full-year EPS guidance. With a 46% payout ratio and growth catalysts from medical devices and its $21 billion Exact Sciences acquisition in cancer diagnostics, Abbott offers both income stability and growth potential.The Motley Fool · Sep 8, 2026

Novocure Reports Patient Data Exposure in Cybersecurity IncidentNovocure Limited (NVCR) disclosed unauthorized access to internal systems in mid-August 2026, exposing internal patient ID numbers for over 1,400 U.S. patients and contact information for healthcare providers and employees. The company stated that medical devices were not accessed, systems remained functional, and no material financial impact is expected. NVCR shares rose 3.2% since the September 1 disclosure.Zacks Investment Research · Sep 7, 2026

Where Will SCHD Stock Be in 5 Years?The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a 57% total return over three years and is recommended as a strong buy for income-focused investors seeking stability and diversification. While the fund offers solid dividend growth (7.53% annually) and exposure to mature, profitable companies, its limited tech exposure (8.2%) means it will miss out on AI-driven gains that boosted the Nasdaq-100 by 92%. The outlook remains positive for the next five years if the U.S. economy continues growing, though trade policy uncertainty and rising bond yields present near-term risks.The Motley Fool · Sep 6, 2026

Schwab U.S. Dividend Equity vs. Vanguard Dividend Appreciation: Which ETF Looks Better for Your Portfolio?Schwab U.S. Dividend Equity ETF (SCHD) offers nearly double the dividend yield of Vanguard Dividend Appreciation ETF (VIG) at 3% versus 1.5%, with a value-focused portfolio in healthcare and consumer defensives. VIG emphasizes technology stocks and requires 10-year dividend growth streaks. SCHD showed stronger one-year returns (29.5% vs 17.1%) and lower volatility, making it the analyst's preferred choice for income investors seeking higher yields.The Motley Fool · Sep 5, 2026

AB

ABTAbbott Laboratories

ABT

Pay with—

Available Balance0.00

Your PositionYou don't own any ABT yet.

Related Tickers

Earnings

Dividends

Last · Jul 15Quarterly

Amount$0.63

Yield2.46%

Annual$2.52